Purity Anti-Estrogen Steroids Hormone Fulvestrante Faslodex for Cutting Cycle 129453-61-8

• Post Date:

  Jul 19,2017

• Expiry Date:

  Jan 15,2018

• Detailed Description:

  Cas No. :129453-61-8 Quantity: 500Kilograms
  Price:2000 USD Kilograms
  
  FulvestrantFaslodex(AstraZeneca)is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.
  
  Fulvestrante is a selective estrogen receptor down-regulator (SERD). Fulvestrante is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrante remains under investigation in an attempt to optimize its effectiveness.
  
  Fulvestrante provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy. In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrante had a lower incidence of joint disorders.

• CAS Registry Number:

  129453-61-8

• Synonyms:

  ;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol;(17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol;Faslodex;

• Molecular Formula:

  C₃₂H₄₇F₅O₃S

• Molecular Weight:

  606.7708

• Molecular Structure:

  

• Company:

  HongKong Blue Universal Co., Limited.     [ China ]        

• Contact:

  Andrew George

• Tel:

  +86-170-76116742

• Fax:

  86-170-76116742

• Email:

  fxhandrew@outlook.com